Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Palliative Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Davies, A.
Right arrow Articles by Beighton, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, A.
Right arrow Articles by Beighton, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer

Andrew Davies

Susan Brailsford

Karen Broadley

David Beighton

Department of Oral Microbiology, GKT Dental Institute, London

The aim of this study was to determine the prevalence of in vitro resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. The National Committee for Clinical Laboratory Standards' broth microdilution method was used to determine the sensitivities to fluconazole, itraconazole, ketoconazole, and nystatin, whilst the Etest® method was used to determine the sensitivity to amphotericin B. The prevalence of in vitro resistance was: amphotericin B, 2%; fluconazole, 8%; itraconazole, 22%; ketoconazole, 7%; nystatin, 0%. Moreover, 28% of the yeasts was resistant to one or more of the azole group of anti-fungal drugs. The results of this study suggest that azole resistance may become a clinical problem in palliative care.

Key Words: anti-fungal agents • Candida • drug resistance • microbial • palliative care

Palliative Medicine, Vol. 16, No. 6, 527-531 (2002)
DOI: 10.1191/0269216302pm583oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
C. E. B. Linares, D. Griebeler, D. Cargnelutti, S. H. Alves, V. M. Morsch, and M. R. C. Schetinger
Catalase activity in Candida albicans exposed to antineoplastic drugs.
J. Med. Microbiol., March 1, 2006; 55(Pt 3): 259 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
J Bagg, M P Sweeney, M A. Lewis, M S Jackson, D Coleman, A A. Mosaid, W Baxter, S McEndrick, and S McHugh
High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer
Palliative Medicine, September 1, 2003; 17(6): 477 - 481.
[Abstract] [PDF]